Lexaria Bioscience

Lexaria's Oral Tirzepatide Formulation Shows Reduced Side Effects, Comparable Efficacy to Injected Zepbound in Early Study

4 months ago

• Lexaria Bioscience's oral DehydraTECH-tirzepatide demonstrated a 47% reduction in adverse events compared to injected Zepbound in a recent human study. • The oral formulation also showed a 54% decrease in gastrointestinal-related side effects, which are commonly associated with GLP-1/GIP drugs. • Blood glucose reduction and insulin secretion levels were comparable between oral DehydraTECH-tirzepatide and injected Zepbound over the 8-day study period. • Lexaria plans to expand its ongoing 12-week study in Australia to further investigate the potential of oral DehydraTECH-tirzepatide at higher doses.

Lexaria Bioscience Receives FDA Clearance for Phase 1b Hypertension Trial of DehydraTECH-CBD

5 months ago

• Lexaria Bioscience has received FDA clearance for its HYPER-H23-1 Phase 1b clinical trial to evaluate DehydraTECH-CBD in patients with stage 1 or 2 hypertension. • The trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DehydraTECH-CBD, building on positive results from previous human clinical studies. • Lexaria's DehydraTECH technology aims to improve the bioavailability of active pharmaceutical ingredients, potentially enhancing the therapeutic effects of CBD. • This milestone supports Lexaria's broader research into DehydraTECH and its application in hypertension and other therapeutic areas, including GLP-1 studies.

Lexaria Bioscience Initiates Phase 1b Study Evaluating DehydraTECH-Enhanced GLP-1 Drugs

5 months ago

• Lexaria Bioscience has begun dosing in its Phase 1b study, GLP-1-H24-4, to assess its DehydraTECH technology's impact on GLP-1 drug safety and efficacy. • The study includes multiple arms testing DehydraTECH-CBD, DehydraTECH-semaglutide, a combination of both, Rybelsus, and potentially DehydraTECH-tirzepatide. • Conducted across seven Australian sites, the study is designed as a 12-week chronic trial and is expected to be recognized as a registrational Phase 1b study by the FDA. • Lexaria aims to determine if DehydraTECH processing enhances weight loss, blood sugar control, and reduces side effects compared to Rybelsus alone.

Lexaria's DehydraTECH GLP-1 Study Receives Ethics Board Approval, Aims to Enhance Oral Delivery of Diabetes and Weight Loss Drugs

6 months ago

• Lexaria Bioscience has received ethics board approval for its Phase 1b study evaluating DehydraTECH-processed GLP-1 drugs for diabetes and weight loss. • The study will compare DehydraTECH-semaglutide, with and without CBD, against Rybelsus® to assess improvements in blood sugar control and weight loss. • Manufacturing of all study arms, including DehydraTECH formulations and Rybelsus® comparator tablets, has been completed, potentially saving months in development time. • The trial, involving 20 overweight or type 2 diabetic patients per arm, will explore the safety and efficacy of oral DehydraTECH-GLP-1 formulations over 12 weeks.

Lexaria's Oral Tirzepatide Study Achieves Dosing Milestone, Eyes on Data

6 months ago

• Lexaria Bioscience has completed dosing in a pilot study evaluating oral tirzepatide, a GLP-1/GIP receptor agonist, utilizing its DehydraTECH drug delivery platform. • The study involved nine healthy volunteers and assessed tolerability, blood absorption, and blood sugar control of the oral formulation compared to injectable tirzepatide. • Lexaria aims to demonstrate meaningful absorption rates of oral tirzepatide, which is currently only available in injectable form, potentially improving patient convenience. • Data analysis is expected in December, with results anticipated in January 2025, which could pave the way for further development of oral GLP-1 therapies.

Lexaria's Oral Tirzepatide Pilot Study Begins Dosing, Evaluating DehydraTECH Delivery

8 months ago

• Lexaria Bioscience has initiated dosing in a human pilot study evaluating an oral formulation of tirzepatide, processed with their DehydraTECH technology. • The study compares the oral DehydraTECH-tirzepatide to injected Zepbound, assessing tolerability, pharmacokinetics, and blood sugar control in healthy volunteers. • Lexaria aims to demonstrate meaningful absorption rates of oral tirzepatide, which is currently only available via injection, potentially improving patient convenience. • This study follows previous successes with DehydraTECH-processed semaglutide, which showed improved absorption and reduced adverse events compared to oral Rybelsus.